NewsBenzingaMorgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359 Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359 Benzinga 2026.10.07 14:22 (GMT+0) Open on Benzinga Other news Healthleap raises $38M for its AI that flags hospital patients who may need a closer look Injective Releases New Whitepaper, Positioning as Institutional-Grade Finance and Asset Tokenization L1 Toshiba Just Issued a Major Warning to Seagate Stock. How to Play STX Here. Tony Fadell on why the first wave of AI gadgets failed — and what comes next Google experiments with an AI-powered gaming platform Why Morgan Stanley and Goldman Sachs May Be Too Bullish on SpaceX Stock
Injective Releases New Whitepaper, Positioning as Institutional-Grade Finance and Asset Tokenization L1
